Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response

D. Di Bella, S. Erzegovesi, M. C. Cavallini, L. Bellodi

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype, interaction for both YBOCS total scores and compulsion scores was found.

Original languageEnglish
Pages (from-to)176-181
Number of pages6
JournalPharmacogenomics Journal
Volume2
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Obsessive-Compulsive Disorder
Genotype
Fluvoxamine
Therapeutics
Tic Disorders
Serotonin Plasma Membrane Transport Proteins
Genetic Promoter Regions
Alleles
Pharmaceutical Preparations
Genes

Keywords

  • Fluvoxamine
  • Pharmacogenetics
  • Serotonin
  • Serotonin reuptake inhibitors
  • Tic disorder

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. / Di Bella, D.; Erzegovesi, S.; Cavallini, M. C.; Bellodi, L.

In: Pharmacogenomics Journal, Vol. 2, No. 3, 2002, p. 176-181.

Research output: Contribution to journalArticle

Di Bella, D, Erzegovesi, S, Cavallini, MC & Bellodi, L 2002, 'Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response', Pharmacogenomics Journal, vol. 2, no. 3, pp. 176-181. https://doi.org/10.1038/sj.tpj.6500090
Di Bella, D. ; Erzegovesi, S. ; Cavallini, M. C. ; Bellodi, L. / Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. In: Pharmacogenomics Journal. 2002 ; Vol. 2, No. 3. pp. 176-181.
@article{c9257f6dbda44b6e9d104d844eec8ca8,
title = "Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response",
abstract = "Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype, interaction for both YBOCS total scores and compulsion scores was found.",
keywords = "Fluvoxamine, Pharmacogenetics, Serotonin, Serotonin reuptake inhibitors, Tic disorder",
author = "{Di Bella}, D. and S. Erzegovesi and Cavallini, {M. C.} and L. Bellodi",
year = "2002",
doi = "10.1038/sj.tpj.6500090",
language = "English",
volume = "2",
pages = "176--181",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response

AU - Di Bella, D.

AU - Erzegovesi, S.

AU - Cavallini, M. C.

AU - Bellodi, L.

PY - 2002

Y1 - 2002

N2 - Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype, interaction for both YBOCS total scores and compulsion scores was found.

AB - Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype, interaction for both YBOCS total scores and compulsion scores was found.

KW - Fluvoxamine

KW - Pharmacogenetics

KW - Serotonin

KW - Serotonin reuptake inhibitors

KW - Tic disorder

UR - http://www.scopus.com/inward/record.url?scp=0036367043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036367043&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500090

DO - 10.1038/sj.tpj.6500090

M3 - Article

C2 - 12082589

AN - SCOPUS:0036367043

VL - 2

SP - 176

EP - 181

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -